Pfizer’s Maddaluna retiring as head of global supply after 41 years with the company

Anthony J. Maddaluna

Pfizer’s executive vice president and president of global supply, Anthony J. Maddaluna, is retiring from the pharma giant after more than 41 years with the company.

Maddaluna first started with Pfizer in 1975 and worked his way up the ranks, holding a number of key positions during his career. He was named president of global supply in 2011, the company said.

“I have had the privilege of working with Tony during much of his career, and he has been a valuable partner to me,” Ian Read, Pfizer’s chairman and chief executive officer, said in a statement. “Tony has continually demonstrated a steadfast commitment to Pfizer and our mission.”

Kirsten Lund-Jurgensen has been named to succeed Maddaluna, effective at the end of the year. She is currently vice president of innovative health product portfolio management and consumer operations.

Prior to joining Pfizer in 1999, Lund-Jurgensen was with SmithKline Beecham, where she held several positions with operational responsibilities.

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.